Trial Profile
Noninterventional Study on the Quality Assurance of the Therapy of Chronic Hepatitis C With Peg-(40kd)-Interferon Alfa-2a (Pegasys®) and Ribavirin (e.g. Copegus®) With Main Focus Gastroenterologists - a Project in BNG (Association of German Resident Gastroenterologists), Part III
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 29 Aug 2020 Results (N=17093) of a pooled analysis of data from five consecutive registries including the German hepatitis C-registry (DHC-R) assessing the knowledge on the evolution of HCV GT 1a vs 1b for understanding HCV epidemiology, presented at The International Liver Congress 2020
- 17 Apr 2014 New trial record